DAX23.933 -0,4%ESt505.371 -0,1%Top 10 Crypto14,25 -1,7%Dow42.127 +0,1%Nas19.213 +0,6%Bitcoin93.865 -2,1%Euro1,1364 +0,6%Öl64,14 -1,3%Gold3.321 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 Tesla A1CX3T Lufthansa 823212 BYD A0M4W9 Siemens Energy ENER6Y Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 D-Wave Quantum A3DSV9 Apple 865985 thyssenkrupp 750000 Deutsche Telekom 555750 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt unter 24.000er-Marke - Rekord außer Reichweite -- NVIDIA über Erwartungen -- US-Gericht erklärt Trumps Zölle für rechtswidrig -- Bilfinger, Tesla, Salesforce im Fokus
Top News
Trotz NVIDIA & Trump-Zoll-Schlappe: DAX schließt unter 24.000er-Marke - Allzeithoch aus den Augen verloren Trotz NVIDIA & Trump-Zoll-Schlappe: DAX schließt unter 24.000er-Marke - Allzeithoch aus den Augen verloren
Vonovia-Aktie rutscht am Ex-Dividenden-Tag ans DAX-Ende - Kursabschlag durch Dividende Vonovia-Aktie rutscht am Ex-Dividenden-Tag ans DAX-Ende - Kursabschlag durch Dividende
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Relmada Therapeutics Aktie

Handeln
Aktien-Sparplan anlegen
0,6350 EUR +0,0750 EUR +13,39 %
FSE
0,7350 USD +0,0131 USD +1,81 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.21,34 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PSZF

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75955J4022

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRLMD

Relmada Therapeutics Aktien News

DatumMeistgelesen
PR NewswireRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
PR NewswireRelmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Wer­bungRelmada Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR NewswireRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR NewswireRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR NewswireRelmada Therapeutics Provides Corporate Update
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
PR NewswireRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
PR NewswireRelmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR NewswireRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
PR NewswireRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
PR NewswireRelmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
PR NewswireRLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD
PR NewswireRelmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
PR NewswireROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMD
PR NewswireRelmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRelmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
PR NewswireRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
PR NewswireRelmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
PR NewswireRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
PR NewswireRLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
PR NewswireRelmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
PR NewswireRelmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
PR NewswireRelmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
PR NewswireRelmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Wer­bung

Relmada Therapeutics News

Relmada Therapeutics News: auf dieser Seite finden Sie alle Relmada Therapeutics News und Nachrichten zur Relmada Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Relmada Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Relmada Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.